GE HealthCare Technologies Prepares for Q3 Earnings Amidst Margin Concerns

Upcoming Earnings and Analyst Expectations

GE HealthCare Technologies (GEHC) is slated to release its third-quarter earnings later this month. The announcement comes as analysts forecast a notable decline in earnings per share, following a period of significant stock underperformance and persistent concerns regarding future margin pressures from international tariffs.

GE HealthCare Technologies Inc. (GEHC) is projected to report third-quarter earnings per share (EPS) of $1.05, according to a consensus of 7 analysts surveyed by Zacks Investment Research. This represents an estimated 7.9% decrease from the $1.14 EPS reported in the same period last year. The upcoming report, scheduled for before market open on October 29, 2025, covers the fiscal quarter ending September 2025.

Recent Underperformance and Market Reaction

The market has reacted with caution to GEHC's recent performance and outlook. Over the past 52 weeks, GEHC stock prices have declined 17.2%, substantially lagging both the Health Care Select Sector SPDR Fund (XLV), which saw a 4.8% dip, and the S&P 500 Index ($SPX), which gained 17.4% during the same timeframe. This underperformance persisted even after the company announced better-than-expected Q2 2025 results on July 30, with revenue reaching $5 billion (a 3.5% year-over-year increase) and EPS of $1.06 surpassing consensus estimates of $0.91. Despite these positive figures, GEHC's stock dropped 7.8% in the trading session following the Q2 release.

Tariff Pressures and Margin Concerns

A primary driver of this sustained pressure is the expectation of continued margin compression in 2025, largely attributed to high tariffs imposed by the U.S. Federal government on goods from the EU and other Indo-Pacific nations. Furthermore, on September 25, 2025, shares fell 4.3% after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, sparking fears of potential new import duties. Earlier in April 2025, the company faced increased tariffs on China, rising from 10% to 54%. While management initially projected a $1.1 billion gross impact from tariffs for 2025, this estimate was later revised downward to $550 million, with hopes for even lower impacts in 2026 if geopolitical conditions stabilize.

Broader Context and Financial Health

GE HealthCare, with a market capitalization ranging from $34 billion to $34.95 billion, is a significant player in the medical technology sector, holding leading market shares in imaging and ultrasound equipment. Its business is diversified across four segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). Geographically, sales are widespread, with 46% from the U.S., 26% from EMEA, 12% from China, and 17% from the rest of the world. The company's 52-week trading range stands between $57.65 and $94.80. Key valuation metrics include a Price-to-Earnings (P/E) ratio of 15.69 and a PEG ratio of 2.93. Financial health indicators show a quick ratio of 0.93, a current ratio of 1.16, and a debt-to-equity ratio of 0.85. For fiscal year 2025, analysts anticipate a full-year EPS of $4.53, an increase from $4.49 in fiscal 2024. The company also maintains a quarterly dividend of $0.035 per share.

The broader healthcare sector, including GEHC, has generally underperformed the wider stock market. This trend is partly attributed to investor apprehension regarding potential reductions in Medicaid and other policy adjustments. The ongoing trade investigations further contribute to uncertainty for global medical device manufacturers.

Evolving Analyst Sentiment

Analyst sentiment regarding GEHC has seen a recent shift. The consensus rating has moved to a “Moderate Buy,” with Citigroup downgrading the stock from a "buy" to a "neutral" on October 7, 2025, and lowering its price target from $93.00 to $83.00. Similarly, Wall Street Zen and Zacks Research downgraded their ratings in September 2025. Despite these adjustments, the average 1-year price target among brokerages remains around $86.89, suggesting a 16.2% upside potential from current levels.

"We are pleased that the global tariff environment has become clearer since our last earnings call. We made significant progress implementing mitigating actions," stated Jay Saccaro, GE HealthCare Vice President and CFO, during the Q2 earnings call, referencing efforts to reduce the impact of tariffs.

Looking Ahead

Investors will closely monitor GE HealthCare Technologies' Q3 earnings report on October 29, 2025, for insights into the actual impact of tariffs and management's updated outlook for 2025 and beyond. The company's ability to navigate tariff complexities and maintain margins will be critical. Further developments in U.S. trade policy, particularly concerning medical equipment, and the performance of the broader healthcare sector will also influence GEHC's trajectory. The recent strategic moves, such as the debut of an AI-supported solution for radiation therapy workflow and the intent to acquire icometrix to bolster its neurology portfolio, may offer long-term growth avenues, but immediate focus will remain on the earnings call and forward guidance.